Palo Alto, California Fears over QT prolongation are mounting for a range of already approved drugs, as well as for agents still in the pipeline. This past week, ranolazine, CV Therapeutics' new ...
SAN FRANCISCO, CA — Researchers presenting new findings on a potential fixed-dose drug combination for a common arrhythmia allowed themselves a good measure of optimism, perhaps an indulgence given ...
Co announces that data published in Circulation and presented at the European Society of Cardiology Congress 2007 in Vienna shows that Ranexa reduced both ventricular and atrial arrhythmias in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback